<code id='BA32059FD0'></code><style id='BA32059FD0'></style>
    • <acronym id='BA32059FD0'></acronym>
      <center id='BA32059FD0'><center id='BA32059FD0'><tfoot id='BA32059FD0'></tfoot></center><abbr id='BA32059FD0'><dir id='BA32059FD0'><tfoot id='BA32059FD0'></tfoot><noframes id='BA32059FD0'>

    • <optgroup id='BA32059FD0'><strike id='BA32059FD0'><sup id='BA32059FD0'></sup></strike><code id='BA32059FD0'></code></optgroup>
        1. <b id='BA32059FD0'><label id='BA32059FD0'><select id='BA32059FD0'><dt id='BA32059FD0'><span id='BA32059FD0'></span></dt></select></label></b><u id='BA32059FD0'></u>
          <i id='BA32059FD0'><strike id='BA32059FD0'><tt id='BA32059FD0'><pre id='BA32059FD0'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:459
          Adobe

          Hospitals and medical groups say they’re still reeling from the effects of the cyberattack on a UnitedHealth Group subsidiary, but the massive company at the center of the debacle has so far emerged largely unscathed, with executives on Tuesday praising its strength and resilience.

          The almost $8 billion UnitedHealth made on operations in the first three months of 2024 was roughly the same as the prior-year period. Despite the Change Healthcare cyberattack, the health insurance, provider, and technology conglomerate reaffirmed its adjusted earnings outlook for the year, and its share price grew more than 5% by market close.

          advertisement

          Ultimately, UnitedHealth said it’ll take an up to $1.6 billion hit from the cyberattack this year, a drop in the bucket for a company that’s expected to generate $400 billion in revenue.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more
          Roche to buy Carmot Therapeutics, developer of obesity drugs
          Roche to buy Carmot Therapeutics, developer of obesity drugs

          SebastienBozon/AFPviaGettyImagesLONDON—Theboomingobesitymarketisattractinganotherplayer,aspharmagian

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          CVS Caremark has created a new ploy: the drug ‘rebate credit’

          ChristineKao/STATThebiggestenticementthatlargepharmacybenefitmanagersoffertotheemployersthathirethem